Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–356 of 356 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Newly Diagnosed Glioblastoma Clear all
Completed Phase 2 Interventional

Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00099125
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
irinotecan hydrochloride, temozolomide, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
118
States / cities
Phoenix, Arizona • Burbank, California • Fresno, California + 91 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 14, 2026, 1:03 AM EDT
Completed Phase 2 Interventional

Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme

NCT01285414
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Verubulin, Temozolomide & Radiation Therapy
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Stanford, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Oct 14, 2026, 1:03 AM EDT
Withdrawn Phase 2 Interventional

Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery

NCT00814593
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
lymphokine-activated killer cells, polifeprosan 20 with carmustine implant
Biological · Drug
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 14, 2026, 1:03 AM EDT
Completed Early Phase 1 Interventional

Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma

NCT01165632
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Myxopapillary Ependymoma, Adult Oligodendroglioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Subependymal Giant Cell Astrocytoma, Adult Subependymoma
Interventions
biopsy, computed tomography, therapeutic conventional surgery, radiation therapy treatment planning/simulation, radiation therapy, magnetic resonance imaging, positron emission tomography, fluorine F 18 fluorodopa
Procedure · Radiation · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 14, 2026, 1:03 AM EDT
Terminated Phase 1 Interventional

Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy

NCT00272870
View directory record Official record
Conditions
Glioblastoma Multiforme (WHO Grade IV), Anaplastic Astrocytoma (WHO Grade III)
Interventions
06Benzylguanine, MGMT P140K, Meltenyi CliniMacs
Drug · Genetic · Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 29, 2012 · Synced Oct 14, 2026, 1:03 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

NCT03491683
View directory record Official record
Conditions
Glioblastoma
Interventions
INO-5401, INO-9012, Cemiplimab, Radiation Therapy, Temozolomide
Biological · Radiation · Drug
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
21
States / cities
Duarte, California • Palo Alto, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 14, 2026, 1:03 AM EDT
Completed Phase 2 Interventional

Radiation Therapy and Tamoxifen in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme

NCT00006388
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
tamoxifen citrate, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
237
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 184 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 14, 2026, 1:03 AM EDT
Recruiting Phase 2 Interventional

Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab

NCT06816927
View directory record Official record
Conditions
Newly Diagnosed Glioblastoma
Interventions
Nivolumab, Relatlimab, TMZ, Radiation Therapy
Drug · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
New York, New York • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 14, 2026, 1:03 AM EDT
Recruiting Phase 1Phase 2 Interventional

Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

NCT02861898
View directory record Official record
Conditions
Glioblastoma, Brain Cancer, Brain Neoplasm, Brain Tumor, Brain Neoplasm, Malignant, EGFR Gene Overexpression, GBM
Interventions
Intra-arterial Cetuximab, Intra-arterial Mannitol
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 14, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation

NCT01402063
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
PPX (CT2103), Temozolomide
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
La Jolla, California • Scarborough, Maine • Worcester, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 14, 2026, 1:03 AM EDT
Recruiting Phase 3 Interventional

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

NCT06556563
View directory record Official record
Conditions
Glioblastoma
Interventions
Optune® device, Temozolomide, Pembrolizumab, Placebo
Device · Drug
Lead sponsor
NovoCure GmbH
Industry
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
36
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 14, 2026, 1:03 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors

NCT00002463
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
MOPP Regimen, Leucovorin Calcium, Mechlorethamine Hydrochloride, Methotrexate, Prednisone, Procarbazine Hydrochloride, Vincristine Sulfate, Conventional Surgery
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 3 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2013 · Synced Oct 14, 2026, 1:03 AM EDT
Completed Phase 3 Interventional

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

NCT00916409
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
NovoTTF-100A device, Temozolomide
Device · Drug
Lead sponsor
NovoCure Ltd.
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 14, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors

NCT00005796
View directory record Official record
Conditions
Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
Interventions
filgrastim, gene therapy, lomustine, procarbazine hydrochloride, vincristine sulfate, in vitro-treated peripheral blood stem cell transplantation
Procedure · Biological · Drug
Lead sponsor
Indiana University
Other
Eligibility
5 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
2
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 14, 2026, 1:03 AM EDT
Completed Early Phase 1 Interventional

Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

NCT01957956
View directory record Official record
Conditions
Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma
Interventions
Laboratory Biomarker Analysis, Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine, Temozolomide
Other · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 14, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT02337426
View directory record Official record
Conditions
Adult Brain Glioblastoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma
Interventions
Dimethyl Fumarate, Temozolomide, Radiation Therapy
Drug · Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 14, 2026, 1:03 AM EDT
Terminated Phase 1 Interventional Results available

EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma

NCT02664363
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
EGFRvIII CAR T cells
Biological
Lead sponsor
Daniel Landi
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 17, 2023 · Synced Oct 14, 2026, 1:03 AM EDT
Active, not recruiting Phase 1 Interventional

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

NCT03749187
View directory record Official record
Conditions
Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation, Low Grade Glioma, Malignant Glioma, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma, WHO Grade III Glioma
Interventions
PARP Inhibitor BGB-290, Temozolomide (TMZ)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years to 39 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 14, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma

NCT03451799
View directory record Official record
Conditions
GBM, Glioblastoma
Interventions
Ketogenic Diet, Standard-of-care radiation, Standard-of-care Temozolomide
Other · Radiation · Drug
Lead sponsor
Jethro Hu
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 14, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)

NCT05698199
View directory record Official record
Conditions
Glioblastoma
Interventions
ITI-1001
Drug
Lead sponsor
Immunomic Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 14, 2026, 1:03 AM EDT